CN109453295A - A kind of pueraria lobata extract tablet formula and preparation method thereof for treating cardiovascular and cerebrovascular disease - Google Patents
A kind of pueraria lobata extract tablet formula and preparation method thereof for treating cardiovascular and cerebrovascular disease Download PDFInfo
- Publication number
- CN109453295A CN109453295A CN201910051067.0A CN201910051067A CN109453295A CN 109453295 A CN109453295 A CN 109453295A CN 201910051067 A CN201910051067 A CN 201910051067A CN 109453295 A CN109453295 A CN 109453295A
- Authority
- CN
- China
- Prior art keywords
- parts
- pueraria lobata
- ginseng
- extract tablet
- cardiovascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a kind of pueraria lobata extract tablet formulas for treating cardiovascular and cerebrovascular disease, it comprises the following components in parts by weight: 10-12 parts of ginseng, Radix Ophiopogonis 10-12 part, 10-12 parts of Schisandra chinensis, 10-14 parts of pueraria lobata, 10-11 parts of ganoderma lucidum, 10-11 parts of Radix Salviae Miltiorrhizae, 10-15 parts of cassia seed, 10-12 parts of pseudo-ginseng, 10-12 parts of borneol, 0.1-0.3 parts of mycin synthetics of deoxidation open country buttocks flavones.The present invention also provides a kind of preparation methods of pueraria lobata extract tablet, weigh each component respectively first, ginseng, Radix Ophiopogonis, Schisandra chinensis, pueraria lobata, ganoderma lucidum, Radix Salviae Miltiorrhizae, cassia seed and pseudo-ginseng are cleaned respectively again, dried, once crushed, is toasted, separating twice, tabletting is carried out after mixing with borneol and deoxidation open country buttocks flavones mycin synthetics to get pueraria lobata extract tablet.Pueraria lobata extract tablet medicinal peace of the invention securely and reliably has no toxic side effect, and has effect outstanding in terms of preventing and treating cardiovascular and cerebrovascular and diabetes.
Description
Technical field
The invention belongs to the field of Chinese medicines, it is specifically related to a kind of pueraria lobata extract tablet formula for treating cardiovascular and cerebrovascular disease
And preparation method thereof.
Background technique
Diabetes are to act on body by a variety of virulence factors, lead to hypoinsulinism, and insulin cannot play accordingly
Adjustment effect, and then cause a series of metabolic disorder syndromes.It is l patients with type Ⅰ DM and 2 type glycosurias that wherein disease incidence is highest
Disease.The clinical manifestation of different type diabetes is different, with hyperglycemia for its common ground.
Type 1 diabetes are mainly shown as that beta Cell of islet is destroyed, insulin content relative deficiency, but body is to pancreas islet
Element is still sensitive, and insulin need to be used for a long time and treated.Diabetes B is mainly shown as beta Cell of islet defect and pancreas islet function
It can imbalance.Diabetes B declines insulin sensitivity, and most of patients does not need long-time service insulin therapy and sustains life.
Diabetic keratopathy cardiovascular disease is the capilary and macroangiopathy for the cardiovascular system that diabetes cause, main to wrap
Include coronary heart disease, diabetic keratopathy cardiovascular autonomic neuropathy, diabetes cardiomyopathy, lower extremity arterial diseases in diabetes mellitus etc..About 1/3
Diabetic there are high triglycerides, hypercholesterolemia.Though some patient's ahyperlipoidemias, can there is lipoprotein
Out of proportion with apolipoprotein fraction, therefore, diabetes are easy concurrent atherosclerosis.Compared with non-diabetic patients, sugar
Disease incidence, the death rate for urinating patient's cardiovascular disease are high, the death rate highest of myocardial infarction.
Therefore treatment diabetes are always research hotspot medically, currently, the drug for treating diabetes is mainly
Chemicals can be mainly divided into following a few classes: (1) sulfonylurea drugs, and insulin contains in function mainly increase body
Amount, to achieve the purpose that control blood glucose.Its hypoglycemic mechanism mainly promotes the potassium-channel of β cell ATP sensitivity to close, from
And stimulating pancreas β cell discharges insulin.But often will appear vomiting, nausea, dysfunction of liver, anaemia, oligoleukocythemia etc.
Adverse reaction；(2) biguanides, mechanism of action are to inhibit excessive endogenous Hepatic glucose production, improve peripheral tissues pair
The sensibility of insulin increases intake and utilization to glucose.Its side effect is mainly gastrointestinal reaction, such as vomiting, abdomen
It rushes down, it is also possible to cause lactic acidosis；(3) glycosidase inhibitor (such as acarbose), the mechanism of action of such drug are competing
ɑ-glycosidase of the inhibition intestinal epithelial cell of striving property, delays starch, disaccharide etc. to resolve into glucose, to slow down glucose
Infiltration rate reduces postprandial blood sugar.The adverse reactions such as common abdominal distension is uncomfortable, stomach and intestine exhaust increases, diarrhea.(4) insulin sensitizer
(such as troglitazone, Rosiglitazone), hypoglycemic mechanism are nuclear receptor-peroxisome proliferators activated receptor γ (PPAR
γ), so that the transcription for influencing the related gene of glycometabolism and the synthesis of protein be made to increase the final effect for enhancing insulin.Water
Swollen, anaemia, water retention are the common adverse reactions of such drug, and troglitazone once caused the hepatic injury of lethal, sieve
Lattice column ketone also has cardiac toxic, can improve the incidence and the death rate of cardiovascular complication.
It can be seen that having apparent side effect using chemotherapy, it is unfavorable for human health, therefore treat diabetes
Drug research direction be transferred on Chinese medicine and Chinese patent drug, however most of prevention and treatment cardiovascular and cerebrovasculars and glycosuria at present
All there is the not significant and expensive defect of slow effect, curative effect in the Chinese medicine of disease, urgent need develop a kind of quick, good effect and
Price material benefit, the safe and reliable, drug that has no toxic side effect, to make patient safe to use.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of quick, good effect and price material benefits, safe and reliable, nothing
Toxic side effect, and it can be effectively prevented and treated the pueraria lobata extract tablet of cardiovascular and cerebrovascular and diabetes, and provide a kind of easy to operate
Preparation method.
The contents of the present invention are as follows:
A kind of pueraria lobata extract tablet formula for treating cardiovascular and cerebrovascular disease, comprises the following components in parts by weight: ginseng 10-12
Part, Radix Ophiopogonis 10-12 part, 10-12 parts of Schisandra chinensis, 10-14 parts of pueraria lobata, 10-11 parts of ganoderma lucidum, 10-11 parts of Radix Salviae Miltiorrhizae, cassia seed 10-15
Part, 10-12 parts of pseudo-ginseng, 10-12 parts of borneol, 0.1-0.3 parts of mycin synthetics of deoxidation open country buttocks flavones.
Preferably, it comprises the following components in parts by weight: 10 parts of ginseng, 12 parts of Radix Ophiopogonis, 12 parts of Schisandra chinensis, 12 parts of pueraria lobata, spirit
11 parts of sesame, 11 parts of Radix Salviae Miltiorrhizae, 12 parts of cassia seed, 12 parts of pseudo-ginseng, 11 parts of borneol, 0.2 part of synthetics of deoxidation open country buttocks flavones mycin.
Alternatively, comprising the following components in parts by weight: 11 parts of ginseng, 11 parts of Radix Ophiopogonis, 11 parts of Schisandra chinensis, 12 parts of pueraria lobata, ganoderma lucidum
10 parts, 10 parts of Radix Salviae Miltiorrhizae, 10 parts of cassia seed, 12 parts of pseudo-ginseng, 12 parts of borneol, 0.3 part of synthetics of deoxidation open country buttocks flavones mycin.
The present invention also provides a kind of preparation methods of the pueraria lobata extract tablet for the treatment of cardiovascular and cerebrovascular disease, including with
Lower step:
(1) each component is weighed according to weight part ratio, borneol levigation is spare；
(2) ginseng, Radix Ophiopogonis, Schisandra chinensis, pueraria lobata, ganoderma lucidum, Radix Salviae Miltiorrhizae, cassia seed and pseudo-ginseng cleaned respectively, are dried, one
Secondary crushing, baking and separating twice, are uniformly mixed and obtain mixture；
(3) borneol after deoxidation open country buttocks flavones mycin synthetics and levigation is added into said mixture, mixing is equal again
Tabletting is carried out after even to get pueraria lobata extract tablet.
Preferably, the drying is dry 2-4h in natural air drying or 30-45 DEG C of drying box.
Preferably, the granularity once crushed is 50-200 mesh.
Preferably, the granularity of the separating twice is 500-800 mesh.
Preferably, the condition of the baking is to toast 2-4h at 40-50 DEG C.
Preferably, the ginseng, pueraria lobata, pseudo-ginseng are first sliced before cleaning, facilitate crushing.
The beneficial effects of the present invention are as follows:
1. the present invention uses this 8 taste Chinese medicine of ginseng, Radix Ophiopogonis, Schisandra chinensis, ganoderma lucidum, Radix Salviae Miltiorrhizae, cassia seed, pseudo-ginseng and borneol, take
With pueraria lobata and deoxidation open country buttocks flavones mycin synthetics, compatibility is good, medicinal peace, can be improved drug effect, quick, good effect,
And price is economical, safe and reliable, has no toxic side effect, can be effectively prevented and treated cardiovascular and cerebrovascular and diabetes, has very big face
Bed meaning.
2. the present invention solves the problems, such as the pueraria lobata essence that traditional Chinese medicine prescribed dose is big, active constituent is indefinite, obtains
Plain piece formula is simple, and preparation is convenient, greatly reduces cost.
3. the pueraria lobata extract tablet for the treatment of cardiovascular and cerebrovascular disease provided by the invention is at low cost, than operative treatment cardiovascular and cerebrovascular
It is more economical, conveniently with diabetes.
Specific embodiment
Embodiment 1:
Each medicinal material: ginseng 10g, Radix Ophiopogonis 12g, Schisandra chinensis 12g, pueraria lobata 12g, ganoderma lucidum 11g, Radix Salviae Miltiorrhizae are weighed by following weight
11g, cassia seed 12g, pseudo-ginseng 12g, borneol 11g, deoxidation open country buttocks flavones mycin synthetics 0.2g.It is first that borneol levigation is spare,
By ginseng, pueraria lobata, pseudo-ginseng slice, then by the ginseng after Radix Ophiopogonis, Schisandra chinensis, ganoderma lucidum, Radix Salviae Miltiorrhizae, cassia seed and slice, pueraria lobata, pseudo-ginseng
It cleaning up, dry 3h in 40 DEG C of drying boxes is carried out once being crushed to granularity later being 200 mesh, then is toasted 3h at 40 DEG C, then
Carrying out separating twice to granularity is 600 mesh, and smashed each component powder is uniformly mixed, and deoxidation open country buttocks flavones is added thereto
Borneol after mycin synthetics and levigation carries out tabletting after mixing to get pueraria lobata extract tablet.
Embodiment 2:
Each medicinal material: ginseng 11g, Radix Ophiopogonis 11g, Schisandra chinensis 11g, pueraria lobata 12g, ganoderma lucidum 10g, Radix Salviae Miltiorrhizae are weighed by following weight
10g, cassia seed 10g, pseudo-ginseng 12g, borneol 12g, deoxidation open country buttocks flavones mycin synthetics 0.3g.It is first that borneol levigation is spare,
By ginseng, pueraria lobata, pseudo-ginseng slice, then by the ginseng after Radix Ophiopogonis, Schisandra chinensis, ganoderma lucidum, Radix Salviae Miltiorrhizae, cassia seed and slice, pueraria lobata, pseudo-ginseng
It cleaning up, dry 4h in 30 DEG C of drying boxes is carried out once being crushed to granularity later being 150 mesh, then is toasted 2h at 50 DEG C, then
Carrying out separating twice to granularity is 500 mesh, and smashed each component powder is uniformly mixed, and deoxidation open country buttocks flavones is added thereto
Borneol after mycin synthetics and levigation carries out tabletting after mixing to get pueraria lobata extract tablet.
Embodiment 3:
Each medicinal material: ginseng 12g, Radix Ophiopogonis 11g, Schisandra chinensis 11g, pueraria lobata 14g, ganoderma lucidum 10g, Radix Salviae Miltiorrhizae are weighed by following weight
10g, cassia seed 10g, pseudo-ginseng 10g, borneol 10g, deoxidation open country buttocks flavones mycin synthetics 0.1g.It is first that borneol levigation is spare,
By ginseng, pueraria lobata, pseudo-ginseng slice, then by the ginseng after Radix Ophiopogonis, Schisandra chinensis, ganoderma lucidum, Radix Salviae Miltiorrhizae, cassia seed and slice, pueraria lobata, pseudo-ginseng
It cleaning up, dry 2h in 45 DEG C of drying boxes is carried out once being crushed to granularity later being 50 mesh, then is toasted 4h at 40 DEG C, then
Carrying out separating twice to granularity is 800 mesh, and smashed each component powder is uniformly mixed, and deoxidation open country buttocks flavones is added thereto
Borneol after mycin synthetics and levigation carries out tabletting after mixing to get pueraria lobata extract tablet.
Comparative example 1:
The Chinese medicine dripping pills obtained using the patent of invention of Patent No. 201510556347.9.
Comparative example 2:
Commercially available insuline pro injection.
Clinical test:
The comparable cardiovascular and cerebrovascular of 300 degree and diabetic are selected, is randomly divided into 3 groups, every group of 100 people.Wherein:
The pueraria lobata extract tablet of first group of oral embodiment 1.
The Chinese medicine dripping pills of second group of oral contrast example 1.
The commercially available insulin of third group intramuscular injection.
Observation after 45 days is as a result, as shown in table 1.
Table 1
| It cures (people) | Effectively (people) | (people) in vain | It is efficient | |
| Embodiment 1 | 30 | 56 | 14 | 86% |
| Comparative example 1 | 18 | 42 | 40 | 60% |
| Comparative example 2 | 11 | 63 | 26 | 74% |
It is bright by table 1 it is found that the effective percentage of the pueraria lobata extract tablet for the treatment of cardiovascular and cerebrovascular disease of the invention reaches 86%
The effect higher than the Chinese medicine dripping pills of comparative example 1 and the intramuscular injection insulin of comparative example 2 is shown, illustrates that pueraria lobata extract tablet formula is adopted
9 taste Chinese medicines and a small amount of deoxidation open country buttocks flavones mycin synthetics compatibility of addition are good, ginseng, Radix Ophiopogonis, Schisandra chinensis, ganoderma lucidum,
Drug effect, quick, treatment can be improved in Radix Salviae Miltiorrhizae, cassia seed, pseudo-ginseng and borneol collocation pueraria lobata and deoxidation open country buttocks flavones mycin synthetics
It imitates, there is effect outstanding in terms for the treatment of cardiovascular and cerebrovascular and diabetes.
Claims (9)
1. a kind of pueraria lobata extract tablet for treating cardiovascular and cerebrovascular disease, which is characterized in that comprise the following components in parts by weight: ginseng
10-12 parts, Radix Ophiopogonis 10-12 part, 10-12 parts of Schisandra chinensis, 10-14 parts of pueraria lobata, 10-11 parts of ganoderma lucidum, 10-11 parts of Radix Salviae Miltiorrhizae, cassia seed
10-15 parts, 10-12 parts of pseudo-ginseng, 10-12 parts of borneol, 0.1-0.3 parts of mycin synthetics of deoxidation open country buttocks flavones.
2. the pueraria lobata extract tablet for the treatment of cardiovascular and cerebrovascular disease as described in claim 1, which is characterized in that including following weight
The component of part: 10 parts of ginseng, 12 parts of Radix Ophiopogonis, 12 parts of Schisandra chinensis, 12 parts of pueraria lobata, 11 parts of ganoderma lucidum, 11 parts of Radix Salviae Miltiorrhizae, 12 parts of cassia seed,
12 parts of pseudo-ginseng, 11 parts of borneol, 0.2 part of synthetics of deoxidation open country buttocks flavones mycin.
3. the pueraria lobata extract tablet for the treatment of cardiovascular and cerebrovascular disease as described in claim 1, which is characterized in that including following weight
The component of part: 11 parts of ginseng, 11 parts of Radix Ophiopogonis, 11 parts of Schisandra chinensis, 12 parts of pueraria lobata, 10 parts of ganoderma lucidum, 10 parts of Radix Salviae Miltiorrhizae, 10 parts of cassia seed,
12 parts of pseudo-ginseng, 12 parts of borneol, 0.3 part of synthetics of deoxidation open country buttocks flavones mycin.
4. a kind of preparation method for the pueraria lobata extract tablet that cardiovascular and cerebrovascular disease is treated as described in claim 1-3 any one,
Characterized by comprising the following steps:
(1) each component is weighed according to weight part ratio, borneol levigation is spare；
(2) ginseng, Radix Ophiopogonis, Schisandra chinensis, pueraria lobata, ganoderma lucidum, Radix Salviae Miltiorrhizae, cassia seed and pseudo-ginseng cleaned respectively, dried, a wheat-middlings
Broken, baking and separating twice, are uniformly mixed and obtain mixture；
(3) borneol after deoxidation open country buttocks flavones mycin synthetics and levigation is added into said mixture, again after mixing
Tabletting is carried out to get pueraria lobata extract tablet.
5. the preparation method of the pueraria lobata extract tablet for the treatment of cardiovascular and cerebrovascular disease as claimed in claim 4, which is characterized in that institute
Stating dry is dry 2-4h in natural air drying or 30-45 DEG C of drying box.
6. the preparation method of the pueraria lobata extract tablet for the treatment of cardiovascular and cerebrovascular disease as claimed in claim 4, which is characterized in that institute
Stating the granularity once crushed is 50-200 mesh.
7. the preparation method of pueraria lobata extract tablet as claimed in claim 4, which is characterized in that the granularity of the separating twice is
500-800 mesh.
8. the preparation method of the pueraria lobata extract tablet for the treatment of cardiovascular and cerebrovascular disease as claimed in claim 4, which is characterized in that institute
The condition for stating baking is to toast 2-4h at 40-50 DEG C.
9. the preparation method of the pueraria lobata extract tablet for the treatment of cardiovascular and cerebrovascular disease as claimed in claim 4, which is characterized in that institute
Ginseng, pueraria lobata, pseudo-ginseng is stated first to be sliced before cleaning.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811314108.2A CN109248259A (en) | 2018-11-06 | 2018-11-06 | A kind of pueraria lobata extract tablet and preparation method thereof |
| CN2018113141082 | 2018-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109453295A true CN109453295A (en) | 2019-03-12 |
Family
ID=65044596
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811314108.2A Pending CN109248259A (en) | 2018-11-06 | 2018-11-06 | A kind of pueraria lobata extract tablet and preparation method thereof |
| CN201910051067.0A Pending CN109453295A (en) | 2018-11-06 | 2019-01-18 | A kind of pueraria lobata extract tablet formula and preparation method thereof for treating cardiovascular and cerebrovascular disease |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811314108.2A Pending CN109248259A (en) | 2018-11-06 | 2018-11-06 | A kind of pueraria lobata extract tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN109248259A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110917293A (en) * | 2019-12-11 | 2020-03-27 | 张家界医源实业有限公司 | Composition for treating diabetes and preparation method thereof |
-
2018
- 2018-11-06 CN CN201811314108.2A patent/CN109248259A/en active Pending
-
2019
- 2019-01-18 CN CN201910051067.0A patent/CN109453295A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109248259A (en) | 2019-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101277710B (en) | Antiobesity composition | |
| US7985848B2 (en) | Pharmaceutical composition for preventing and treating diabetes or glucose control abnormality comprising ginsenosides | |
| CN102273621B (en) | A kind of food of prevention and therapy diabetes or health food | |
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN109221898A (en) | A kind of grain dust and its preparation method and application containing xylo-oligosaccharide | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| CN102935116A (en) | Pharmaceutical compositions or health care product having blood sugar reduction effect | |
| CN107714794A (en) | Russia's color extract tablet and preparation method thereof | |
| CN109453295A (en) | A kind of pueraria lobata extract tablet formula and preparation method thereof for treating cardiovascular and cerebrovascular disease | |
| CN102552299B (en) | Application of dioscin in preparing medicament for preventing and treating diabetes mellitus | |
| CN107319332A (en) | A kind of integration of drinking and medicinal herbs composition with hypoglycemic effect and preparation method thereof | |
| CN110693029A (en) | Mulberry leaf and bitter gourd functional food capable of reducing blood sugar | |
| CN106110294A (en) | A kind of nutritional preparation repairing damaged islet cells and preparation method thereof | |
| CN1799582A (en) | Blood sugar- and blood pressure-lowering medicine | |
| CN109771578A (en) | The composition for preventing and treating diabetes and complication | |
| CN109223811A (en) | Panaxsaponin composition with hypoglycemic activity | |
| CN100496561C (en) | Medicine for improving sugar tolerance and treating diabetes and its preparation process | |
| CN100361649C (en) | Prepn process of alive adult roach extract | |
| EP3978009A1 (en) | Traditional chinese medicine increase and decrease prescription for preventing/treating metabolic syndrome and complications thereof | |
| CN107260946A (en) | A kind of health-care edible capsule preparation method with auxiliary hyperglycemic function | |
| CN107375665A (en) | A kind of Chinese medicine preparation for treating diabetes and preparation method thereof | |
| CN107136499A (en) | Compound preparation for enhancing immunity of tumor patients after operation | |
| CN106619613A (en) | Application of bilobalide serving as brain-targeting synergist to preparation of drug for preventing brain tumor | |
| CN110840996A (en) | Traditional Chinese medicine formula, method, preparation and application for treating qi-yin deficiency metabolic syndrome | |
| CN1298351C (en) | Chinese medicine oral preparaton for treating urinary system infestation and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190312 |